

Please type a plus sign (+) inside this box -



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/978,303
		Filing Date	October 15, 2001
		First Named Inventor	Jullus
		Group Art Unit	1646
		Examiner Name	To Be Assigned
Sheet 1 of 2	Attorney Docket Number	UCSF084CON	

RECEIVED  
 APR 09 2002  
 TECH CENTER 1600/1900

U.S. PATENT DOCUMENTS						
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
		6,239,267		SmithKline	05/29/2001	
		6,335,180		The Regents of the University of California	01/01/2002	
✓		6239267	B1	Duckworth et al	05/29/2001	
✓		6335180	B1	JULLUS et al	01/01/2002	

FOREIGN PATENT DOCUMENTS								
Examiner Initials'	Cite No. <sup>1</sup>	Foreign Patent Documents			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
✓			EP 0953638		Snythelabo	03/11/1999		
			EP 0943 683		Smithkline Beecham	09/22/1999		
✓			WO 00/29577		Millennium Pharmaceuticals	05/25/2000		
			WO 00/32766		Glaxo Group Limited	06/08/2000		
✓			WO 00/63415		Ortho-McNeil Pharmaceuticals, Inc.	10/26/2000		

Examiner Signature	<i>Tom</i>	Date Considered	7-10-03
--------------------	------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →




PTO/SB/08A (08-00)


Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/PTO				<b>Complete if Known</b>			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number		09/978.303	
				Filing Date		October 15, 2001	
				First Named Inventor		Julius	
				Group Art Unit		1646	
				Examiner Name		To Be Assigned	
				Attorney Docket Number		UCSF084CON	
Sheet	2	of	2				
				WO 01/34805	Abbott Laboratories	05/17/2001	
				WO 99/37765	SmithKline Beecham	07/29/1999	
				WO 99/46377	Sanofi-Snythelabo	09/16/1999	
				EP 1 160 254	Pfizer, Inc.	05/12/2001	
				WO 01/68857	Millennium Pharmaceuticals	09/20/2001	



OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>

Examiner Signature		Date Considered	7-10-03
-----------------------	--	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

09/78303



<b>INFORMATION DISCLOSURE CITATION</b> Form PTO-1449 (Modified) (Use several sheets if necessary)	ATTY. DOCKET NO. UCSF084CON	SERIAL NO. To Be Assigned
	APPLICANT Julius, et al.	
	FILING DATE October 15, 2001	GROUP To Be Assigned

### U.S. PATENT DOCUMENTS

Examiner's Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
✓	AA	5,074,977	12/24/91	Cheung, et al.	204	153	10/23/90
✓	AB	5,232,684	08/03/93	Blumberg, et al.			06/29/90
✓	AC	5,234,566	08/10/93	Osman, et al.	204	403	04/18/91
✓	AD	5,328,847	07/12/94	Case, et al.	435	291	11/18/91
✓	AE	5,443,955	08/22/95	Cornell, et al.	435	7.21	07/03/91
✓	AF	5,491,097	02/13/96	Ribi, et al.	436	518	02/28/94

### FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
✓	EP	EP 0953638A1	11/03/99	Europe				

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

✓	AG	Appendio and Szallasi, AEuphorbium: Modern Research on its Active Principle, Resiniferatoxin, Revives an Ancient Medicine, @ <i>Life Sciences</i> , 60(10): 681-696 (1997).
✓	AH	Bevan and Szolcsányi, ASensory Neuron-Specific Actions of Capsaicin: Mechanisms and applications, @ <i>Tips</i> , Vol. 11 (Aug 1990).
✓	AI	Bevan and Docherty, <i>Capsaicin in the Study of Pain</i> , Chapter 2: ACellular Mechanisms of the Action Capsaicin, @ pp. 27-44. Academic Press Ltd. (1993).


EXAMINER	DATE CONSIDERED 9-10-01
----------	-------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE CITATION</b> Form PTO-1449 (Modified) (Use several sheets if necessary)	ATTY. DOCKET NO. UCSF084CON	SERIAL NO. To Be Assigned
	APPLICANT Julius, et al.	
	FILING DATE October 15, 2001	GROUP To Be Assigned

**OTHER ART** (Including Author, Title, Date, Pertinent Pages, Etc.)

2	AJ	Fusco and Giacobazzo, APeppers and Pain,@ Drugs, 53(6): 909-914 (Jun 1997).
2	AK	Campbell, et al., <i>Capsaicin in the Study of Pain</i> , Chapter 12: AClinical Applications of Capsaicin and Its Analogues,@ pp. 255-273. Academic Press Ltd. (1993).
2	AL	Caterina, et al., "The Capsaicin Receptor: A Heat-Activated Ion Channel in the Pain Pathway," <i>Nature</i> <b>389:816-824</b> (23 October 1997).
2	AM	James, et al., Capsaicin in the Study of Pain, Chapter 5: AThe Capsaicin Receptor,@ pp. 83-104. Academic Press Ltd. (1993).
2	AN	Koplas, et al, AThe Role of Calcium in the Desensitization of Capsaicin Responses in Rat Dorsal Root Ganglion Neurons,@ <i>Journal of Neuroscience</i> , 17(10): 3525-3537 (May 15, 1997).
2	AO	Liu, et al., AThe Responses of Rat Trigeminal Ganglion Neurons to Capsaicin and Two Nonpungent Vanilloid Receptor Agonists, Olvanil and Glycerlyl Nonamide,@ <i>Journal of Neuroscience</i> , 17(11): 4101-4111 (Jun 1, 1997).
2	AP	Nagy, et al., "Cobalt Uptake Enables Identification of Capsaicin- and Bradykinin-Sensitive Supopulations of Rat Dorsal Root Ganglion Cells In Vitro," <i>Neuroscience</i> <b>56(1):241-246</b> (1993).
2	AQ	Rang, et al., Textbook of Pain, Chapter 3: ANociceptive Peripheral Neurons: Cellular Properties,@ pp. 57-78.
2	AR	A. Maureen Rouhi, AChili Pepper Studies Paying off with Hot Birdseed and Better Analgesics,@ <i>Chemical and Engineering News</i> , pp. 30-31 (Mar 4, 1996).
2	AS	J. Szolcsányi, <i>Capsaicin in the Study of Pain</i> , Chapter 1: AActions of Capsaicin on Sensory Receptors,@ pp. 1-26. Academic Press Ltd. (1993).
2	AT	Towheed and Hochberg, AA Systematic Review of Randomized Controlled Trials of Pharma-cological Therapy in Osteoarthritis of the Knee, with an Emphasis on Trial Methodology,@ <i>Semin. Arthritis Rheum.</i> 26(5): 755-770 (Apr 1997)

EXAMINER 	DATE CONSIDERED 7-10-07
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<b>INFORMATION DISCLOSURE CITATION</b> Form PTO-1449 (Modified) (Use several sheets if necessary)	ATTY. DOCKET NO. UCSF084CON	SERIAL NO. To Be Assigned
	APPLICANT Julius, et al.	
	FILING DATE October 15, 2001	GROUP To Be Assigned

2	AU	Wood, et al., ACapsaicin-Induced Ion Fluxes Increase Cyclic GMP But Not Cyclic AMP Levels in Rat Sensory Neurons in Culture, @ <i>Journal of Neurochemistry</i> , 53(4): 1203-1211 (1989).
2	AV	GenBank Accession No. H20025
2	AW	GenBank Accession No. AA236416
2	AX	GenBank Accession No. H51393
2	AY	GenBank Accession No. AA236417
2	AZ	GenBank Accession No. H27879
2	BA	GenBank Accession No. H50364
2	BB	GenBank Accession No. N21167
2	BC	GenBank Accession No. AA461295
2	BD	GenBank Accession No. N26729
2	BE	GenBank Accession No. H21490
2	BF	GenBank Accession No. H49060
2	BG	GenBank Accession No. AA281349
2	BH	GenBank Accession No. W44731
2	BI	GenBank Accession No. N23395
2	BJ	GenBank Accession No. W38665
2	BK	GenBank Accession No. AA357145
2	BL	GenBank Accession No. N24224
2	BM	GenBank Accession No. W92895
2	BN	GenBank Accession No. T12251
2	BO	GenBank Accession No. AA304033
2	BP	GenBank Accession No. N35179
2	BQ	GenBank Accession No. AA281348
2	BR	GenBank Accession No. W82502

EXAMINER <i>Jan ~</i>	DATE CONSIDERED <i>7-10-01</i>
-----------------------	--------------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE CITATION</b> Form PTO-1449 (Modified) (Use several sheets if necessary)	ATTY. DOCKET NO.	SERIAL NO.
	UCSF084CON	To Be Assigned
	APPLICANT	
	Julius, et al.	
	FILING DATE	GROUP
	October 15, 2001	To Be Assigned

✓	BS	GenBank Accession No. W53556
✓	BT	GenBank Accession No. AA139413
✓	BU	GenBank Accession No. AA76107
✓	BV	GenBank Accession No. AA015295
✓	BW	GenBank Accession No. AA274980
✓	BX	GenBank Accession No. AA321554
✓	AA	Szallasi, et al., "Characterization of a Peripheral Vanilloid (Capsaicin) Receptor in the Urinary Bladder of the Rat," <i>Life Sciences</i> <b>52(20)</b> :221-226 (1993).
✓	AB	Wardle, et al., "Pharmacological Characterization of the Vanilloid Receptor in the Rat Isolated Vas Deferens," <i>J. Pharm. Pharmacol.</i> <b>48</b> :285-291 (1996).
✓	AA	Biro et al. (1997) "Recent Advances in Understanding of Vanilloid Receptors: A Therapeutic Target for Treatment of Pain and Inflammation in Skin." <i>Journal of Investigative Dermatology Symposium Proceedings</i> , Vol. 2:56-60.
✓	AB	Szallasi (1994) "The Vanilloid (Capsaicin) Receptor: Receptor Types and Species Differences." <i>Gen. Pharmac.</i> , Vol. 25(2):223-243.

EXAMINER	<i>John A.</i>	DATE CONSIDERED	<i>7-10-01</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			